CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments. The biological response of lymphoma cells and the immune system to this drug combination will also be measured in patients before, during, and after therapy administration.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Collaborator: Bayer
• Treatments: Alemtuzumab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine

Criteria

Inclusion Criteria:

• CD-20 Negative

• Previous treatment permitted: radiation, electron beam radiotherapy, PUVA, corticosteroids, IFN, low dose methotrexate, retinoids, Ontak

• CNS disease permitted

Exclusion Criteria:

• Pregnant or Nursing

• prior Alemtuzumab

• history of active Hep C